Pillar · Dermatological research
Skin, Hair and Aesthetic Peptide Research
Dermatology has the strongest human research base of any peptide application area, because skin is accessible: biopsies, imaging and controlled topical application make measurable endpoints practical. This hub covers copper peptides, signal peptides and carrier peptides, what has been demonstrated in controlled skin studies, and where hair-follicle research currently stands.
Evidence position
Emerging human research
Research evidence, established clinical evidence and regulatory approval are three different things. This page distinguishes them throughout and does not present research compounds as approved treatments.
How topical peptides are classified
Dermatological peptides are usually grouped by mechanism. Signal peptides stimulate matrix protein production, most often collagen. Carrier peptides deliver trace elements such as copper to enzymes that require them. Neurotransmitter-inhibiting peptides interfere with acetylcholine release at the neuromuscular junction. Enzyme-inhibiting peptides reduce matrix degradation. Each group has a distinct evidence profile.
Copper peptide research
GHK-Cu is the most-studied member of the group. Human and ex-vivo skin work has examined collagen and glycosaminoglycan synthesis, antioxidant gene expression and wound-healing endpoints. The findings are reasonably consistent for skin-quality measures. Hair research is thinner: follicle studies exist, but controlled trials with objective hair-count endpoints are limited.
The penetration question
The stratum corneum excludes most molecules above roughly 500 daltons. Many cosmetic peptides exceed that, so formulation — penetration enhancers, encapsulation, particle carriers — often determines whether a peptide reaches viable epidermis at all. A study demonstrating activity in cultured fibroblasts says nothing about whether the same peptide crosses intact skin in a finished formulation.
Compounds studied in this area
| Compound | What it is | Evidence tier |
|---|---|---|
| GHK-Cu | Copper-binding tripeptide; the most-researched dermatological peptide. | Emerging human research |
| Matrikine signal peptides | Collagen-fragment-derived sequences studied for matrix stimulation. | Emerging human research |
| Melanocortin-related peptides | Sequences studied in pigmentation and related pathways; associated with notable safety concerns. | Early laboratory research |
Comparisons in this cluster
Key takeaways
- Dermatology has the strongest human research base of any peptide application area, because skin is accessible: biopsies, imaging and controlled topical application make measurable endpoints practical. This hub covers copper peptides, signal peptides and carrier peptides, what has been demonstrated in controlled skin studies, and where hair-follicle research currently stands.
- Overall evidence position for this topic: emerging human research.
- Findings in cells or animals are hypotheses about humans, never demonstrations in humans.
- Nothing on this page is medical advice, a protocol, or a dosing recommendation.
Frequently asked questions
Do copper peptides increase collagen?
Controlled skin studies have reported increased collagen and glycosaminoglycan synthesis with GHK-Cu. Effect sizes vary by study design, formulation and endpoint measurement.
Do peptides help hair growth?
Follicle-level research exists, but controlled human trials using objective hair-count endpoints are limited. The evidence does not support strong claims.
Continue reading
Related research hubs
Peptide Science
How peptides are built, how they signal, how they are synthesised and how they are studied — the foundational science behind every other topic on this site.
Regenerative Peptides
BPC-157, TB-500, GHK-Cu and related sequences studied in tendon, ligament, muscle and wound-healing models — mechanisms, evidence tiers and honest limitations.
Peptide Safety
What is actually known about peptide safety — immunogenicity, contamination, unknown long-term profiles, and why absence of reported harm is not evidence of safety.
About this page
Written and reviewed by the Peptide Intel Hub Editorial Team. Last reviewed 8 September 2026.
Scientific disclaimer: this page is educational and does not constitute medical advice. Research compounds referenced here are not approved treatments. See our research disclaimer.